en · de · es · fr · pt
faq-desk.peptides6579.com › News › Semax Peptide Background And Identity — Background and Details

Semax Peptide Background And Identity — Background and Details

By Editorial Desk · published 2025-12-28 · last reviewed 2026-02-07 · News

Everything below concerns Neurotrophic signalling. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.

Semax Peptide Background and Identity

Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.

Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Mechanisms and Research Directions

Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.

Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.

Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.

Semax at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptide (ACTH fragment analog)Not a steroid; does not belong to the melanocortin agonist drugs by marketing category
Molecular formulaC37H51N9O10S (commonly cited)Reported values vary slightly with salt and counter-ion content
AppearanceWhite to off-white lyophilized powderA single batch may appear as a loose cake or fluffy solid
SolubilityFreely soluble in water and aqueous bufferStock solutions are usually prepared in sterile water or saline
Typical storage−20 °C or below, desiccated and protected from lightSeal opened vials promptly to limit moisture uptake

Semax Background And Mechanism

The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.

Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.

Related pages on this site

Handling, Storage, and Analytical Methods

Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.

Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.

Background and Development History

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.

Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.

Background from the literature

An immunogen is any substance that generates B-cell (humoral/antibody) and/or T-cell (cellular) adaptive immune responses upon exposure to a host organism. Immunogens that generate antibodies are called antigens ("antibody-generating"). Immunogens that generate antibodies are directly bound by host antibodies and lead to the selective expansion of antigen-specific B-cells. Immunogens that generate T-cells are indirectly bound by host T-cells after processing and presentation by host antigen-presenting cells. An immunogen can be defined as a complete antigen which is composed of the macromolecular carrier and epitopes (determinants) that can induce immune response. An explicit example is a hapten. Haptens are low-molecular-weight compounds that may be bound by antibodies, but cannot elicit an immune response. Consequently, the haptens themselves are nonimmunogenic and they cannot evoke an immune response until they bind with a larger carrier immunogenic molecule. The hapten-carrier complex, unlike free hapten, can act as an immunogen and can induce an immune response. Until 1959, the terms immunogen and antigen were not distinguished.

=== April === 29 April – The Federal Senate rejects Attorney-General Jorge Messias' nomination to the Supreme Federal Court in a 34–42 vote, the first time since 1894 that a presidential nominee to the court has been rejected. 30 April – Congress overrides president Lula's veto of a bill that would have reduced former president Bolsonaro's prison sentence.

The developing lung is particularly vulnerable to changes in the levels of vitamin A. Vitamin A deficiency has been linked to changes in the epithelial lining of the lung and in the lung parenchyma. This can disrupt the normal physiology of the lung and predispose to respiratory diseases. Severe nutritional deficiency in vitamin A results in a reduction in the formation of the alveolar walls (septa) and to notable changes in the respiratory epithelium; alterations are noted in the extracellular matrix and in the protein content of the basement membrane. The extracellular matrix maintains lung elasticity; the basement membrane is associated with alveolar epithelium and is important in the blood-air barrier. The deficiency is associated with functional defects and disease states. Vitamin A is crucial in the development of the alveoli which continues for several years after birth.

=== Complications === Compartment syndrome is a clinical diagnosis, i.e., no diagnostic test conclusively proves its presence or absence, but direct measurement of the pressure in a fascial compartment, and the difference between this pressure and the blood pressure, may be used to assess its severity. High pressures in the compartment and a small difference between compartment pressure and blood pressure indicate that the blood supply is likely to be insufficient, and that surgical intervention may be needed. Disseminated intravascular coagulation, another complication of rhabdomyolysis and other forms of critical illness, may be suspected based on unexpected bleeding or abnormalities in hematological tests, such as a decreasing platelet count or prolongation of the prothrombin time. The diagnosis can be confirmed with standard blood tests for DIC, such as D-dimer.

== Function == Several lines of evidence suggest that PD-1 and its ligands negatively regulate immune responses. PD-1 knockout mice have been shown to develop lupus-like glomerulonephritis and dilated cardiomyopathy on the C57BL/6 and BALB/c backgrounds, respectively. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. IFN-γ is a key pro-inflammatory cytokine that promotes T cell inflammatory activity. Reduced T cell proliferation was also correlated with attenuated IL-2 secretion and together, these data suggest that PD-1 negatively regulates T cell responses. Experiments using PD-L1 transfected DCs and PD-1 expressing transgenic (Tg) CD4+ and CD8+ T cells suggest that CD8+ T cells are more susceptible to inhibition by PD-L1, although this could be dependent on the strength of TCR signaling. Consistent with a role in negatively regulating CD8+ T cell responses, using an LCMV viral vector model of chronic infection, Rafi Ahmed's group showed that the PD-1-PD-L1 interaction inhibits activation, expansion and acquisition of effector functions of virus specific CD8+ T cells, which can be reversed by blocking the PD-1-PD-L1 interaction. Expression of PD-L1 on tumor cells inhibits anti-tumor activity through engagement of PD-1 on effector T cells. Expression of PD-L1 on tumors is correlated with reduced survival in esophageal, pancreatic and other types of cancers, highlighting this pathway as a target for immunotherapy.

Sources: en.wikipedia.org

Reference notes

"Anatomy diagram: 34256.000-1". Roche Lexicon - illustrated navigator. Elsevier. Archived from the original on 2012-12-27. "Anatomy diagram: 34256.000-2". Roche Lexicon - illustrated navigator. Elsevier. Archived from the original on 2013-06-11.

where the λi are the Lagrange multipliers, one for each element. This allows each of the Nj and λj to be treated independently, and it can be shown using the tools of multivariate calculus that the equilibrium condition is given by

Jean-Louis Sebagh is an Algerian-born French cosmetic surgeon and doctor who is known for his anti-aging surgeries, and use of botox, collagen and vitamin injections specifically on the face and neck. Sebagh's high profile clients including numerous celebrities, models and socialites include Cindy Crawford, Elle McPherson and Kylie Minogue. and he has offices in Paris and London.

The US Navy dispatched two naval battle groups built around the aircraft carriers USS Dwight D. Eisenhower and USS Independence to the Gulf, where they were ready by 8 August. The US sent the battleships USS Missouri and USS Wisconsin. 48 US Air Force F-15s from the 1st Fighter Wing at Langley Air Force Base, Virginia, landed in Saudi Arabia and commenced round-the-clock air patrols of the Saudi–Kuwait–Iraq border to discourage Iraqi military advances. They were joined by 36 F-15 A-Ds from the 36th Tactical Fighter Wing at Bitburg, Germany. The Bitburg contingent was based at Al Kharj Air Base. The 36th TFW would be responsible for 11 confirmed Iraqi Air Force aircraft shot down during the war. Two Air National Guard units were stationed at Al Kharj Air Base, the South Carolina Air National Guard's 169th Fighter Wing flew bombing missions with 24 F-16s flying 2,000 combat missions and dropping four million pounds (1,800,000 kilograms; 1,800 metric tons) of munitions, and the New York Air National Guard's 174th Fighter Wing from Syracuse flew 24 F-16s on bombing missions. Military buildup continued, reaching 543,000 troops, twice that used in the 2003 invasion. Much of the material was airlifted or carried to the staging areas via fast sealift ships, allowing a quick buildup. Amphibious exercises were carried out in the Gulf, including Operation Imminent Thunder, which involved the USS Midway and 15 other ships, 1,100 aircraft, and a thousand Marines.

Sources: en.wikipedia.org

Reference notes

== Function == mTOR integrates the input from upstream pathways, including insulin, growth factors (such as IGF-1 and IGF-2), and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway is a central regulator of mammalian metabolism and physiology, with important roles in the function of tissues including liver, muscle, white and brown adipose tissue, and the brain, and is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers. Rapamycin inhibits mTOR by associating with its intracellular receptor FKBP12. The FKBP12–rapamycin complex binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR, inhibiting its activity.

=== Sarcomere assembly === In addition to sarcomere activity, it has been shown that myomesin also plays a role in the assembly of the sarcomere. In order for myomesin to be implemented into the sarcomere, myosin and titin must be present, indicating that myomesin is the last component to be added during assembly of the lattice. It is believed that this postponed addition is due to the role of myomesin to act as an "integrity check" to ensure the sarcomere has been formed correctly and monitor its integrity. This is extremely important as if even one piece of the M-line is missing, the A-band of the sarcomere will collapse and the muscle will be paralyzed.

== Research == Elaunin fibers have been found within the secretory coil of human eccrine sweat glands. They were found in bundles of microtubules which had a different constancy than elastic fibers. The elaunin fibers found in the secretory coil had a less thick appearance than that of elastic fibers. Elaunin can be identified where the fibers of the gingival ligament are. There are elastic fibers, and one of the main types of elastic fibers is elaunin. In the papillary dermis, elaunin is lost when in reduction. Proteins such as Fibulin-5 keep elastic fibers organized and functional. Fibulin-5 levels can drop due to normal aging or damage caused by UV exposure, this makes the elastic fibers start to lose its structure. They contribute to maintaining elasticity but are also sensitive to environmental stress and the natural aging process.

Sources: en.wikipedia.org

Frequently asked questions

What is Semax made of?

It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.

Where did Semax originate?

It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.

Is Semax a licensed medicine?

It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.

What is the leading proposed mechanism?

The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.

Network